TP53 mutations are associated with significantly poorer outcomes in patients with AML/MDS, including inferior remission rates, shorter overall survival, and higher relapse rates relative to patients with wild‐type TP53.3, 4, 5, 6, 7. This evidence concerns the gene TP53 and myelodysplastic syndrome.